Welcome to our dedicated page for Mei Pharma SEC filings (Ticker: MEIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lite Strategy, Inc. filings document the company’s corporate transition from MEI Pharma, including the amended certificate of incorporation that changed its name and the Nasdaq ticker change from MEIP to LITS. Recent 8-K disclosures also record its Litecoin treasury reserve strategy, related Regulation FD announcements, and financial-results reporting tied to treasury operations.
The company’s filings cover material agreements and capital-structure matters, including a private placement of common stock and pre-funded warrants, the GSR asset-management relationship, and a BitGo Prime master loan framework for digital assets or cash. Governance disclosures include board changes, stockholder voting results, and approval of the 2026 Omnibus Equity Compensation Plan.
MEI Pharma, Inc. entered a master loan agreement with BitGo Prime, LLC on September 3, 2025 that creates a framework for the company to borrow digital assets or cash under separately negotiated loan requests. Each loan will specify principal, fees, collateral requirements, and term; fees (the effective interest) are set and calculated daily at the annualized rate shown in each confirmation.
Borrowings under the agreement are secured by collateral that is typically required to exceed the borrowed amount and are subject to margin calls; failure to maintain collateral can lead to default remedies including collateral liquidation. The agreement also includes customary representations, covenants, and events of default. A copy of the master agreement is filed as Exhibit 10.1.
MEI Pharma, Inc. (Nasdaq: MEIP) filed an amended shelf registration on Form S-3/A describing resale of registered shares by selling stockholders and certain warrant terms. The prospectus states 32,837,743 shares of common stock outstanding as of August 25, 2025, assuming full exercise of several warrant series. The company discloses potential gross proceeds if warrants are exercised: approximately $394 from the Pre-Funded Warrants in full, $6.0 million from Asset Manager Warrants, $1.8 million from Strategic Advisor Warrants, and $4.8 million from Placement Agent Warrants, and states any proceeds received would be used to purchase Litecoin.
The filing details transfer agent information (Computershare), indemnification provisions for directors and officers under Delaware law, and risks including cybersecurity threats to digital assets and custody-related losses. It describes the Pre-Funded Warrant mechanics (initial exercise price $0.0001, exercisability, cashless exercise, ownership limits), resale methods for selling stockholders, and incorporation by reference of prior SEC reports and audited financial statements.
MEI Pharma, Inc. (Nasdaq: MEIP) filed an amended shelf registration on Form S-3/A describing resale of registered shares by selling stockholders and certain warrant terms. The prospectus states 32,837,743 shares of common stock outstanding as of August 25, 2025, assuming full exercise of several warrant series. The company discloses potential gross proceeds if warrants are exercised: approximately $394 from the Pre-Funded Warrants in full, $6.0 million from Asset Manager Warrants, $1.8 million from Strategic Advisor Warrants, and $4.8 million from Placement Agent Warrants, and states any proceeds received would be used to purchase Litecoin.
The filing details transfer agent information (Computershare), indemnification provisions for directors and officers under Delaware law, and risks including cybersecurity threats to digital assets and custody-related losses. It describes the Pre-Funded Warrant mechanics (initial exercise price $0.0001, exercisability, cashless exercise, ownership limits), resale methods for selling stockholders, and incorporation by reference of prior SEC reports and audited financial statements.
MEI Pharma director Joshua Riezman was granted a stock option to buy 10,000 shares of common stock at an exercise price of $5.19. The option was granted on 08/08/2025, becomes exercisable in installments and expires on 08/08/2035. The grant vests in 36 equal monthly installments, with the first installment vesting one month after the grant, subject to continued service.
Joshua Riezman, a director of MEI Pharma, Inc. (MEIP), filed an Initial Statement on Form 3 reporting the event date 08/05/2025. The filing states that no securities are beneficially owned by the reporting person. The Form 3 was signed by an attorney-in-fact on 08/20/2025 and includes an Exhibit 24 Power of Attorney.
This Schedule 13G reports that Alexander Schornstein beneficially owns 2,115,000 shares of MEI Pharma common stock, representing 6.53% of the outstanding class based on 32,367,236 shares reported in the issuer's registration statement. The filing states that 1,890,000 shares are held directly and 225,000 shares are held by Camino Capital GmbH, for which Mr. Schornstein is the sole beneficial owner.
The report shows sole voting power over 2,115,000 shares and sole dispositive power over 2,065,000 shares, and includes a certification that the securities were not acquired to change or influence control of the issuer. The filer is identified as a citizen of Germany with a listed residence address.
MEI Pharma, Inc. (MEIP) filed an 8-K dated August 5, 2025 reporting Regulation FD disclosure and other events related to digital asset purchases. The company acquired 929,548 Litecoin (LTC) at an average price of $107.58 during July 30–August 4, 2025, deploying all net proceeds from a PIPE private placement dated July 17, 2025. MEI states it is the first U.S.-listed public company to adopt Litecoin as a primary reserve asset and is implementing a new strategy built on digital asset infrastructure and long-term capital innovation. A press release is furnished as Exhibit 99.1. The filing does not disclose the aggregate USD value of the purchases or additional valuation details.